China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced the proposed spin-off and separate listing of its subsidiary, WuXi XDC Cayman Inc. (WuXi XDC, HKG: 2268), on the Hong Kong Stock Exchange’s Main Board.
WuXi XDC’s Specialized Services in Bioconjugates and ADCs
WuXi XDC, a joint venture between WuXi Biologics and WuXi STA, specializes in providing end-to-end contract research, development, and manufacturing services for bioconjugates, including antibody drug conjugates (ADCs). The company’s comprehensive services range from antibodies and other biologics intermediates to chemical payloads and linkers, as well as bioconjugate drug substances and drug products. WuXi XDC has demonstrated exceptional efficiency in advancing ADC projects, with the ability to reach the Investigational New Drug (IND) filing stage in 15 months or less, nearly halving the traditional development timeline.
Ongoing Projects and Financial Performance of WuXi XDC
As of May 2023, WuXi XDC has 102 integrated projects under development, including 44 post-IND bioconjugate projects, with 14 of these projects in phase II/III. This showcases the company’s robust pipeline and commitment to innovation in the bioconjugate space. In 2022, WuXi XDC generated RMB 990 million (USD 125 million) in revenues, highlighting its financial strength and market potential.-Fineline Info & Tech
